Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Payables (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Payables data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Payables fell 63.86% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 63.86%, while the annual FY2025 figure was $1.2 million, 63.86% down from the prior year.
  • Payables reached $1.2 million in Q4 2025 per CLDX's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Payables topped out at $4.3 million in Q3 2025 and bottomed at $685000.0 in Q2 2021.
  • Average Payables over 5 years is $2.2 million, with a median of $2.2 million recorded in 2022.
  • The widest YoY moves for Payables: up 331.56% in 2024, down 68.93% in 2024.
  • A 5-year view of Payables shows it stood at $1.2 million in 2021, then skyrocketed by 171.99% to $3.3 million in 2022, then increased by 4.61% to $3.5 million in 2023, then dropped by 6.55% to $3.3 million in 2024, then tumbled by 63.86% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.2 million in Q4 2025, $4.3 million in Q3 2025, and $2.1 million in Q2 2025.